BD 211875 - Adjuvant Complete H37 RA Mycobacterial Adjuvant for Immunological Research Applications

BD 211875 - Adjuvant Complete H37 RA Mycobacterial Adjuvant for Immunological Research Applications

The BD 231131 Adjuvant Complete H37 RA is a specialized immunological reagent formulated for research applications requiring strong immune response stimulation. This complete adjuvant contains inactivated Mycobacterium tuberculosis strain H37Ra, incorporated into an oil-based emulsion to enhance antigen presentation and immune activation.

Widely used in experimental immunology, this adjuvant is designed to boost both humoral and cell-mediated immune responses when combined with specific antigens. It plays a critical role in vaccine development studies, antibody production, and immunological assays conducted in controlled laboratory environments.

The formulation is optimized to ensure consistency, potency, and reproducibility, making it a trusted choice for researchers working in academic, pharmaceutical, and biotechnology laboratories.

Key Benefits

The inclusion of inactivated mycobacterial components significantly enhances immune system activation, enabling stronger and more sustained immune responses compared to incomplete adjuvants.

The oil-based emulsion provides slow antigen release, improving immune system exposure and increasing the effectiveness of immunization protocols.

Its standardized composition ensures reliable and reproducible results across experiments, which is essential for research accuracy and data integrity.

The product is manufactured under strict quality control, ensuring safety and consistency for laboratory use.

Compatibility and Applications

BD Adjuvant Complete H37 RA is compatible with a wide range of protein, peptide, and microbial antigens used in immunological research. It is typically mixed with the antigen prior to administration in experimental models.

This product is commonly used in vaccine research, antibody production, immunogenicity studies, and experimental disease models. It is suitable for use in academic research institutions, pharmaceutical laboratories, and biotechnology facilities.

Usage Guidelines

The adjuvant should be emulsified with the antigen according to established laboratory protocols before administration. Proper mixing techniques are essential to ensure a stable and uniform emulsion.

Use only in controlled research environments by trained personnel. Follow institutional guidelines for handling biological reagents and ensure proper dosing and administration techniques.

Refer to the manufacturers instructions for detailed preparation, handling, and storage recommendations to maintain product integrity and effectiveness.

Certifications and Safety Standards

The BD 231131 Adjuvant Complete H37 RA is produced under ISO-certified manufacturing processes, ensuring high standards of quality and consistency. Each batch undergoes rigorous quality control testing to verify performance and safety.

This product is intended for research use and is manufactured in compliance with applicable laboratory reagent standards. Its production adheres to strict regulatory guidelines to ensure reliability in scientific applications.

Comparison with Competitors

Compared to alternative complete adjuvants, BD Adjuvant Complete H37 RA offers superior consistency and well-characterized performance. The use of the H37Ra strain provides a reliable and widely recognized standard for immunological studies.

BDs formulation ensures stable emulsification and predictable immune response, whereas some competing products may show variability in composition or effectiveness.

The trusted reputation of BD in laboratory and diagnostic products further enhances confidence in its performance compared to less established brands.

Typical User Profile and Application Scenarios

This product is intended for use by immunologists, biomedical researchers, and laboratory scientists involved in vaccine development, antibody production, and immunological research.

It is commonly used in controlled laboratory experiments, including preclinical studies and research focused on understanding immune mechanisms. It is not intended for clinical or therapeutic use in humans.

Best Practices for Use and Maintenance

Store the adjuvant according to recommended temperature conditions to preserve its stability and effectiveness. Avoid repeated freeze-thaw cycles, which may compromise the emulsion quality.

Always prepare emulsions using sterile techniques to prevent contamination. Ensure thorough mixing to achieve a consistent formulation before use.

Handle with care and use appropriate personal protective equipment when working with biological reagents. Dispose of unused material and waste in accordance with institutional biosafety guidelines.

Regulatory and Safety Information

The BD Adjuvant Complete H37 RA is intended strictly for research use and should not be used for diagnostic or therapeutic purposes. It complies with applicable standards for laboratory reagents and research materials.

Users must follow all relevant biosafety and regulatory requirements when handling and disposing of the product. Proper documentation and adherence to institutional protocols are essential for safe and compliant use.

How to Order

To order the BD 231131 Adjuvant Complete H37 RA, add the product to your cart and proceed through the secure checkout process on CIA Medical.

For bulk orders, research procurement support, or additional information, contact CIA Medical customer service at (312) 275-5850. Their team is available to assist with your purchasing needs.